Method for using type II pneumocytes in pulmonary fibrosis

摘要

It describes the use of type II pneumocytes as inhibitory agents of fibroblast proliferation, for which reason they can be used in the preparation of a drug for the treatment of lung diseases which present with pulmonary fibrosis.

主权项

1. A method of reducing collagen deposition induced by pulmonary fibrosis comprising:
intratracheally administering a pharmaceutical composition comprising autologous or allogeneic type II pneumocytes to a subject in need of treatment, and reducing collagen deposition induced by pulmonary fibrosis, wherein the type II pneumocytes have the following characteristics: 1) the presence of bodies of laminar inclusions which constitute pulmonary surfactant, apical microvilli, cell-cell junctions and a cuboidal shape, 2) can differentiate into type I pneumocytes, and 3) can synthesize, store and secrete pulmonary surfactant.